Establishing The First Southern Chinese Haplobank Of Clinical-Grade hiPSCs

Gain practical insight into bringing pluripotent stem cell workflows closer to clinical readiness with scalable, automated approaches. Chao Sheng highlights established strategies for closed-system expansion and differentiation of human PSCs using integrated adherent cell culture processes and GMP-grade media, supporting consistency, reduced contamination risk, and smoother tech transfer. Complementing the workflow perspective, Camie Chan shares how Xellera built Hong Kong’s first commercial cGMP facility for cell and gene therapies, along with the region’s first haplobank of clinical-grade hiPSCs—offering a real-world view of infrastructure, regulatory navigation, and supply considerations.